Zymenex Gets US Orphan Approval

Zymenex A/S, focused on products for the treatment of rare, genetic diseases has been granted Orphan Designation in the USA by the FDA. The designation concerns a Zymenex enzyme used in the treatment of metachromatic leukodystrophy, a disease that causes irreparable neurological damage and death. The enzyme has previously been granted Orphan status in the EU. Phase II trials have been going for a year in Europe, and Phase II trials will begin in the US.

For further information please contact:

Jens Fogh,

President, CEO

Tel: + 45 48 25 00 54

Email zxmail@zymenex.com

Or visit: www.zymenex.com

Home > News & Events > News > Zymenex Gets US Orphan Approval
Last updated: 2008-04-22

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

ZYMENEX A/S

ZYMENEX A/S

Zymenex is engaged in the research and development of safe and effective pharmaceutical products for rare genetic diseases. The initial goal is to develop a successive number of enzyme replacement therapies for these diseases. Zymenex A/S is a Danish/Swedish biotech company, which is registered in ...